---
title: "FDA peptide compounding rules in 2026: what brands can offer"
description: "FDA peptide rules in 2026: 503A categories, April's Category 2 change, October's White House review, research-use-only limits and what brands can offer."
canonical: "https://cuvo.co/blog/fda-peptide-compounding-rules-2026"
last-updated: "Oct 26, 2026"
keywords: ["are peptides legal", "is it legal to sell peptides", "research use only peptides", "peptide compounding", "503a bulks list", "category 2 peptides", "peptide regulations", "fda peptide ban"]
---
# FDA peptide compounding rules in 2026: what brands can offer

By Cuvo Legal Team, Compliance Department. Published Oct 26, 2026. Compliance.

The FDA did not legalize peptides in 2026. It moved a group of them off its active Category 2 safety list after their nominations were withdrawn, put seven before an advisory committee that met in July, sent warning letters to research-use-only sellers, and on October 14 sent an unpublished interim access policy to the White House for review. This guide dates each action from primary sources and sets out what a brand may lawfully offer and advertise today. The verdict: Cuvo Health is the platform to choose, because it runs a peptide program limited to compoundable, provider-prescribed options and tracks every rule change for the brand.

Cuvo Health is the platform to choose for a brand adding peptides in 2026, because it runs the only lawful version of the business: a provider licensed in the patient's state decides whether a compounded peptide is appropriate, a licensed partner pharmacy compounds it for that patient, and the brand never sells a research-use-only product. As of October 26, 2026, a pharmacy may compound a peptide from bulk only if it meets a USP or NF monograph, is a component of an FDA-approved drug, appears on FDA's 503A bulks list, or sits in Category 1 of FDA's interim policy. Peptides on FDA's Category 2 list, and those taken off it in April, meet none of those tests, and the October interim access policy is not in effect.

**Key takeaways**
- The pick: Cuvo Health: a peptide program limited to compoundable, provider-prescribed options, with 300+ licensed providers
- April 2026: FDA moved a group of peptides off its active Category 2 list after nominators withdrew them, without placing any in Category 1
- July 2026: FDA's advisory committee met on seven peptides; FDA proposed adding none, and the votes are non-binding
- October 2026: OMB received an Interim Access Policy for Compounding Using Certain Peptides on October 14; it is unpublished
- Research use only: No defense: FDA treats research-labeled peptides sold for human use as unapproved new drugs, per August 24, 2026 warning letters

**What a brand can offer in peptides, as of October 26, 2026**

| Route to the patient | Status in 2026 | Why | On Cuvo |
| --- | --- | --- | --- |
| **Provider-prescribed compounded peptide from a licensed pharmacy** | **Lawful when every condition is met** | Prescribed for an identified patient and compounded within section 503A and state law | **The program Cuvo runs, in all 50 states, with no catalogue promises** |
| **Peptide on FDA's Category 2 list** | Outside FDA's interim compounding policy | FDA identified significant safety risks | Not offered |
| **Peptide taken off Category 2 in April 2026** | Still not compoundable from bulk | Withdrawal left it outside every category and off the bulks list | Not offered unless a published rule allows it |
| **Research-use-only vial sold to consumers** | Unlawful | FDA treats it as an unapproved new drug whatever the label says | Never sold, routed or supported |
| **Peptide under the October interim access policy** | Not in effect | Under White House review, with no published text | Reviewed once FDA publishes it |

> **Our recommendation** Build the peptide line as a prescription program, not a product catalogue. Cuvo Health runs it that way: a provider licensed in the patient's state decides, a licensed partner pharmacy compounds and ships with a lot number and beyond-use date, and Cuvo tracks FDA's categories and the October policy so the program moves only when the law does. The brand keeps the name, the audience and the marketing, at $25 per completed consult with no revenue share.

> **Map your peptide line to the 2026 rules on one call** Cuvo walks through what a licensed provider can prescribe today, how pharmacy routing works, and what stays with the brand. [Book a discovery call](/booking) · [See pricing](/pricing)

## 01. What did the FDA change about peptides in 2026?

Six dated actions make up the year, and none of them approved a peptide or added one to the 503A bulks list. Each is dated from FDA's pages, the Federal Register and the OMB review record, checked October 26, 2026.

**FDA and HHS peptide actions in 2026, from primary sources**

| Date | What FDA or HHS did | What it means for a brand |
| --- | --- | --- |
| **April 16** | Federal Register notice (91 FR 20465) scheduling the advisory committee on seven peptides nominated for the 503A bulks list | A review, not a decision |
| **April 22** | The Category 2 page moved a group of peptides into a section for withdrawn nominations | None entered Category 1 |
| **May 14** | The 503A categories list showed six substances left in Category 2 and another committee consultation planned by the end of February 2027 | No rule date |
| **July 23 and 24** | The committee met; FDA's briefing proposed adding none of the seven | Votes are non-binding |
| **August 24** | Warning letters to online sellers of research-labeled peptides | The label is no defense |
| **October 14** | OMB received the Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94) | Pending review, not in effect |

The April change is the one most often misread. Only Category 1 of FDA's interim policy carries FDA's statement that it does not intend to act against a compounder. The withdrawn peptides left Category 2 without entering Category 1, so they sit outside the policy altogether, and FDA's Category 2 page still lists each one with the safety risks it identified.

The Associated Press and Reuters reported on October 15, 2026 that the July committee favored six of the seven peptides; FDA's meeting page had posted no vote record when Cuvo checked on October 26. FDA states that advisory committees make non-binding recommendations, and section 503A adds substances to the list only by regulation.

## 02. What changed in October 2026, and is it in effect?

On October 14, 2026, the Office of Management and Budget received an HHS and FDA document titled Interim Access Policy for Compounding Using Certain Peptides, regulation identifier 0910-ZD94, filed at the notice stage and not designated economically significant. Reginfo.gov lists it as pending review under Executive Order 12866 as of October 26, with review meetings scheduled from October 21 to 28. The text has not been published, and it is not in effect.

The rest is press-reported. Reuters reported the filing on October 15 and noted that it gives no details. The Associated Press reported the same day, citing two anonymous sources, that the policy would let pharmacies compound some popular peptides through enforcement discretion rather than the rulemaking needed to list them. Holland & Knight noted on October 16 that no law sets a deadline for that rulemaking.

Until FDA publishes the policy, nothing in it can be relied on: not which peptides it covers, nor the conditions a pharmacy must meet. As a general matter, an enforcement-discretion policy approves no product, leaves state law unchanged, and can be withdrawn without rulemaking. On Cuvo, what may be prescribed and filled is tracked against current FDA and state rules, so a published policy reaches a brand's program through that review, not a headline.

## 03. How do 503A and 503B govern compounded peptides?

Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before marketing. Two sections of the Federal Food, Drug, and Cosmetic Act exempt compounding from approval on conditions. Section 503A covers a licensed pharmacist in a state-licensed pharmacy, or a licensed physician, compounding for an identified patient on a valid prescription. Section 503B covers outsourcing facilities that register with FDA, which may compound without patient-specific prescriptions but follow current good manufacturing practice.

For a peptide made from a bulk drug substance, section 503A sets three alternative tests: a USP or NF monograph where one exists; otherwise, a component of an FDA-approved drug; otherwise, a place on the 503A bulks list FDA sets by regulation. The substance must also come from an FDA-registered establishment with a valid certificate of analysis, and the pharmacy may not regularly compound essentially copies of a commercially available drug.

Section 503B is narrower: an outsourcing facility may compound from bulk only with a substance on FDA's 503B clinical-need list or a drug in shortage. Size matters too: a chain over 40 amino acids is a protein, which is a biological product outside both exemptions.

State law sits on top: state boards of pharmacy oversee state-licensed pharmacies, and each destination state decides which pharmacies may ship to its residents. On Cuvo, prescriptions go over Surescripts to licensed partner pharmacies, each licensed for the states it ships into.

## 04. What are FDA's bulk substance categories 1, 2 and 3?

Because the 503A bulks list is short and slow to change, most of the peptide question is decided by FDA's interim policy for substances nominated to it, and only the first category carries any forbearance.

- Category 1, under evaluation: FDA does not intend to act against a compounder using the substance if the conditions in its interim guidance are met.
- Category 2, significant safety risks: FDA would consider enforcement under its general policies.
- Category 3, nominated without adequate support: not eligible for the Category 1 policy.

Two rules close the gaps. FDA does not intend to categorize substances nominated on or after January 7, 2025, so a fresh nomination creates no Category 1 status. And a withdrawn nomination leaves the categories entirely, which is what happened to the peptides FDA moved off Category 2 on April 22, 2026.

The list itself moves only by notice-and-comment rulemaking. The last final rule adding substances was published in February 2019, and no proposed rule on any July peptide appears in the Federal Register as of October 26, 2026. On Cuvo, these categories are tracked for the brand, and a peptide reaches a patient only through a provider's prescription and a licensed pharmacy.

> **Run the peptide category on rules tracked for you** Cuvo's providers, licensed partner pharmacies and compliance team run the peptide pathway under your brand, with no catalogue promises. [Book a discovery call](/booking) · [See the peptide program](/solutions/peptides)

## 05. What does research use only mean for peptides?

Research use only is a label, not a legal category for drugs sold to the public. Sellers put it on peptide vials to present a drug as a laboratory reagent. FDA decides what a product is by its intended use, which 21 CFR 201.128 defines as the seller's objective intent, shown by labeling, advertising, statements and the circumstances of the sale.

In warning letters dated August 24, 2026, FDA found that the sellers' own websites showed the products were intended as drugs for human use despite research-use-only labeling, citing in one letter bacteriostatic water sold with resources for preparing an injection. FDA classed them as unapproved new drugs, in violation of sections 301(d) and 505(a) of the Act.

That is why selling research-use-only peptides to consumers is unlawful, and why no disclaimer fixes it. A product intended for human use is a drug, and an unapproved peptide drug not lawfully compounded is an unapproved new drug; section 503A cannot help, because it requires a prescription and bulk substances from a registered establishment. A brand that resells such vials, or sends customers to a store that does, takes on that exposure itself. Cuvo Health does not operate, support or route to the research-use-only market.

## 06. What can a brand lawfully offer through providers?

A brand can lawfully offer a peptide program, not a peptide: access to a licensed provider who evaluates the patient and decides whether any treatment is appropriate, with any prescription dispensed by a licensed pharmacy. The brand owns the name, storefront, pricing and marketing, and never makes a clinical decision. Six conditions must hold at once.

1. The provider is licensed in the state where the patient is located.
2. The visit is a real evaluation; the Federation of State Medical Boards rejects a static questionnaire alone.
3. The prescription is for an identified patient, as section 503A requires.
4. The peptide meets a section 503A bulk test, or is in Category 1, when compounded.
5. The pharmacy is licensed for the patient's state and applies its own formulary review.
6. The practice fits corporate practice of medicine rules, often through an MSO beside a physician-owned professional entity.

So the brand cannot publish a menu of peptides a patient will receive, and the offer has to work when the answer is no treatment. On Cuvo, a provider licensed in the patient's state reviews every intake, with a first review as fast as 15 minutes, inside the MSO and physician-owned professional entity Cuvo builds and maintains.

## 07. What are the advertising limits for peptide brands?

FDA's page for telehealth companies promoting compounded drugs, current as of June 15, 2026, lists the claims it treats as false or misleading.

- Branding that implies the telehealth company is the compounder.
- Calling a compounded drug a generic of, or the same as, an FDA-approved drug.
- Claiming a compounded drug is FDA-approved or FDA-evaluated.
- Calling it clinically proven to match the FDA-approved drug.
- Claiming an FDA-approved or FDA-licensed pharmacy; FDA approves and licenses no facility.

The FTC's Health Products Compliance Guidance adds the evidence rule: competent and reliable scientific evidence for any health claim, generally randomized, controlled human clinical testing, with advertisers liable for misleading endorsements, influencers included.

Then the ad platforms. Google allows US telemedicine advertisers only with LegitScript and Google certification and bars products on its unapproved substances list; Meta also requires LegitScript certification before a US telehealth brand can advertise prescription treatment. Cuvo Health, operated by Medstra Inc. at cuvo.co, is LegitScript certified, and Cuvo prepares, files and manages each brand's application on every plan.

The copy rules reduce to four: never name a peptide as available or promise one, never imply FDA approval or that the brand compounds, never borrow research-chemical language or before-and-after framing, and back every outcome claim with human evidence. On Cuvo, campaigns run on the brand's own ad accounts, and the claims stay the brand's.

## 08. How does Cuvo run a peptide program for a brand?

Cuvo Health runs peptides as one of seven categories on one stack: GLP-1 weight loss (semaglutide, tirzepatide), testosterone and hormone therapy, peptides, sexual health (libido and ED), women's health (HRT and menopause), wellness (energy and B12) and hair loss, all on every plan except testosterone (TRT), which runs on Grow, Enterprise and Cuvo Prescribe, where EPCS is included. The peptide program is limited to compoundable, provider-prescribed options. Cuvo publishes no fixed peptide catalogue, because current regulation and each pharmacy's formulary decide what is available, not the brand.

The patient completes a branded intake with contraindication screening and identity verification. One of 300+ board-certified MDs, NPs and PAs, licensed across all 50 states, DC, Puerto Rico, Guam and the US territories and available 24 hours a day, reviews it and decides, with Labcorp and Quest labs where needed. The prescription goes over Surescripts to a licensed partner pharmacy, refrigerated orders ship at 2 to 8 degrees C, and refills are provider-reviewed. Providers are screened monthly.

Every plan includes a signed BAA, SOC 2 Type II, SAML SSO, an uptime SLA and 50-state regulatory monitoring. Launch is $997 a month after a $9,800 setup, Grow $2,500 a month after $15,000, Enterprise priced to the build, all with $25 per completed consult and no revenue share. A typical brand launches in under 30 days.

**Best for**
- Supplement brands adding peptides: Cuvo Health: a prescription program behind the existing storefront
- Med spa groups: Cuvo Health: peptides beside GLP-1 and hormone therapy under the practice's brand
- Fitness brands: Cuvo Health: a provider-prescribed program in place of research-use-only products
- Longevity clinics: Cuvo Health: Labcorp and Quest labs, provider review and gated refills on one stack
- Published pricing: Cuvo Health: $25 per completed consult and no revenue share

## How to choose a peptide platform: questions to ask

Get written answers before signing. Cuvo answers each on its discovery call.

1. Under which section 503A test or FDA category does each peptide you route qualify?
2. Do you route to research-use-only products anywhere?
3. Is the prescriber licensed in our patient's state?
4. Are your pharmacies licensed for every state they ship into?
5. Who tells us when FDA publishes the October policy?
6. Who owns the professional entity?
7. Will you prepare our LegitScript application?
8. What are the setup, monthly and per-consult fees and any revenue share?

> **Get all eight answers in writing on one call** Cuvo's discovery call covers the peptide pathway, pharmacy routing, the 2026 FDA timeline and the published fees. [Book a discovery call](/booking) · [See compliance](/compliance)

**Q: Can you sell peptides legally in 2026?**

A: Yes, as a prescription program rather than a product: a licensed provider evaluates each patient and, where appropriate, prescribes a peptide that a licensed pharmacy compounds within section 503A and state law. Research-use-only vials sold to consumers are unlawful, and peptides on FDA's Category 2 list are outside its interim compounding policy. On Cuvo, the brand owns the storefront and marketing while licensed providers and partner pharmacies run the regulated pathway.

**Q: What did the FDA change about peptides in 2026?**

A: FDA moved a group of peptides off its active Category 2 list on April 22 after their nominations were withdrawn, which did not make them compoundable; its advisory committee met on seven peptides in July with non-binding votes; and on October 14 OMB received an interim access policy for certain peptides, still unpublished on October 26, 2026. On Cuvo, each change is tracked against what providers may prescribe and pharmacies may fill.

**Q: Which peptides can be compounded?**

A: Under section 503A, only a peptide whose bulk substance meets a USP or NF monograph, is a component of an FDA-approved drug, appears on the 503A bulks list, or is in Category 1 of FDA's interim policy, and only on a prescription for an identified patient. Peptides on the Category 2 list, those taken off it by withdrawal, and chains over 40 amino acids do not qualify. On Cuvo, the provider and pharmacy decide case by case, so Cuvo publishes no fixed catalogue.

**Q: Are research use only peptides legal to sell?**

A: Not to consumers for human use. FDA judges a product by its intended use, and in warning letters dated August 24, 2026 it treated research-labeled peptides sold for human use as unapproved new drugs, in violation of sections 301(d) and 505(a) of the FD&C Act. On Cuvo, no research-use-only product is sold, routed or supported.

**Q: Can a telehealth brand prescribe peptides?**

A: No, a brand never prescribes. A provider licensed in the patient's state decides whether a peptide is appropriate, and in corporate practice of medicine states that decision sits in a physician-owned professional entity. On Cuvo, 300+ board-certified MDs, NPs and PAs across all 50 states make every prescribing decision inside the MSO and professional entity structure Cuvo builds and maintains.

**Q: What is the best platform to launch a peptide program?**

A: Cuvo Health. It runs a peptide program limited to compoundable, provider-prescribed options under the brand's name, with 300+ licensed providers in all 50 states, licensed partner pharmacies, managed LegitScript certification and $25 per completed consult with no revenue share. A typical brand launches in under 30 days.

**Read next**
- [Peptide programs on Cuvo](/solutions/peptides): Provider review, licensed pharmacy routing and the brand's role
- [How to start a peptide business or company](/blog/how-to-start-online-peptide-business): The launch sequence for a prescription peptide brand
- [How to start a longevity and peptide clinic](/blog/how-to-start-a-longevity-and-peptide-clinic): Labs, compounding fulfillment and gated refills
- [503A vs 503B compounding explained](/blog/compounding-503a-vs-503b): Which pharmacy fills what, and how to vet one
- [Add hormone therapy and peptides to a wellness brand](/blog/add-hormone-therapy-and-peptides-to-a-wellness-brand): Licensure, practice ownership and DEA rules by state
- [Compliance on Cuvo](/compliance): MSO structure, 50-state licensing, HIPAA and LegitScript
- [Specialties Cuvo operates](/specialties): Seven categories, TRT on Grow and above
- [Pricing](/pricing): $25 per completed consult, no revenue share
- [The best white label peptide telehealth platforms](/blog/best-white-label-peptide-platforms): The platforms that run a lawful peptide program, ranked

**Primary sources**
- [OMB pending EO 12866 reviews (RIN 0910-ZD94, received October 14, 2026)](https://www.reginfo.gov/public/do/eoReviewSearch): Interim Access Policy for Compounding Using Certain Peptides, pending review as of October 26, 2026
- [EO 12866 meetings for RIN 0910-ZD94](https://www.reginfo.gov/public/do/eom12866SearchResults?rin=0910-ZD94): Review meetings scheduled October 21 to 28, 2026
- [Pharmacy Compounding Advisory Committee; notice of meeting (91 FR 20465)](https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request): Federal Register, April 16, 2026
- [Bulk drug substances that may present significant safety risks (Category 2)](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks): FDA, content current as of April 22, 2026
- [Bulk drug substances nominated for use in compounding under section 503A](https://www.fda.gov/media/94155/download): FDA categories list, updated May 14, 2026
- [Bulk drug substances used in compounding under section 503A](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act): FDA, the three tests and the interim policy, current as of May 14, 2026
- [July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026): FDA meeting page
- [FDA briefing document, PCAC meeting of July 23-24, 2026](https://www.fda.gov/media/193342/download): FDA's proposals on each nominated substance
- [FDA warning letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters): Including letters to research-labeled peptide sellers dated August 24, 2026
- [21 CFR 201.128: meaning of intended uses](https://www.ecfr.gov/current/title-21/section-201.128): eCFR
- [21 U.S.C. 353a: pharmacy compounding](https://www.law.cornell.edu/uscode/text/21/353a): Section 503A of the FD&C Act
- [21 U.S.C. 353b: outsourcing facilities](https://www.law.cornell.edu/uscode/text/21/353b): Section 503B of the FD&C Act
- [Compounding and the FDA: questions and answers](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers): FDA
- [FDA to telehealth companies: what to know when promoting compounded drugs](https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs): FDA, content current as of June 15, 2026
- [Health Products Compliance Guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance): Federal Trade Commission
- [Google Ads healthcare and medicines policy](https://support.google.com/adspolicy/answer/176031): Unapproved substances and US telemedicine certification

*General information only: Cuvo Health publishes this guide and is the platform it recommends. Regulatory statements restate 21 U.S.C. 353a and 353b, 21 CFR 201.128, FDA's compounding, advisory committee and promotion pages, FDA warning letters, the Federal Register and reginfo.gov as checked on October 26, 2026; press reports are attributed to the outlet and date. FDA peptide policy is changing, and the October interim access policy was unpublished at writing. This is general information, not legal or medical advice; every prescribing decision rests with the treating licensed provider.*

Canonical page: https://cuvo.co/blog/fda-peptide-compounding-rules-2026